Table 1.
Patients’ characteristics of 146 ESCC patients and patients’ clinicopathological characteristics according to pCR.
| Characteristic | Total (n = 146),% | pCR (n = 42),% | Non-pCR (n = 104),% | P |
|---|---|---|---|---|
| Age (yrs) | 0.992 | |||
| ≤55 | 59(40.4) | 17(40.5) | 42(40.4) | |
| >55 | 87(59.6) | 25(59.5) | 62(59.6) | |
| Sex | 0.039 | |||
| Male | 128(87.7) | 33(78.6) | 95(91.3) | |
| Female | 18(12.3) | 9(21.4) | 9(8.7) | |
| KPS | 0.717 | |||
| Median | 80(70–90) | 80(70–90) | 80(70–90) | |
| Smoking | 0.231 | |||
| Yes | 74(50.7) | 18(42.9) | 56(53.8) | |
| No | 72(49.3) | 24(57.1) | 48(46.2) | |
| Prognostic nutrition index | 0.404 | |||
| <49 | 74(50.7) | 19(45.2) | 55(52.9) | |
| ≥49 | 72(49.3) | 23(54.8) | 49(47.1) | |
| Tumor location | 0.189 | |||
| Upper | 40(27.4) | 16(38.1) | 24(23.1) | |
| Middle | 85(58.2) | 21(50.0) | 64(61.5) | |
| Distal | 21(14.4) | 5(11.9) | 16(15.4) | |
| Primary tumor length | 0.837 | |||
| <7cm | 68(46.6) | 19(45.2) | 49(47.1) | |
| ≥7cm | 78(53.4) | 23(54.8) | 55(52.9) | |
| Clinical T stage | 0.217 | |||
| T2 | 3(2.1) | 1(2.4) | 2(1.9) | |
| T3 | 96(65.8) | 32(76.2) | 64(61.5) | |
| T4 | 47(32.2) | 9(21.4) | 38(36.5) | |
| Clinical N stage | 0.859 | |||
| N0 | 27(18.5) | 9(21.4) | 18(17.3) | |
| N1 | 70(47.9) | 21(50.0) | 49(47.1) | |
| N2 | 45(30.8) | 11(26.2) | 34(32.7) | |
| N3 | 4(2.7) | 1(2.4) | 3(2.9) | |
| Clinical TNM stage | 0.208 | |||
| II | 19(13.0) | 8(19.0) | 11(10.6) | |
| III | 79(54.1) | 24(57.1) | 55(52.9) | |
| IV | 48(32.9) | 10(23.8) | 38(36.5) | |
| Radiation dose (Gy) | 0.030 | |||
| <40 | 35(24.0) | 5(11.9) | 30(28.8) | |
| ≥40 | 111(76.0) | 37(88.1) | 74(71.2) | |
| Radiotherapy modality | 0.497 | |||
| 2DRT | 68(46.6) | 22(52.4) | 46(44.2) | |
| 3DRT | 8(5.5) | 3(7.1) | 5(4.8) | |
| IMRT | 70(47.9) | 17(40.5) | 53(51.0) | |
| Chemotherapy cycle | 0.552 | |||
| 1 | 47(32.2) | 12(28.6) | 35(33.7) | |
| ≥2 | 99(67.8) | 30(71.4) | 69(66.3) | |
| yp T stage | – | |||
| T0 | 50(34.2) | 42(100) | 8(7.7) | |
| T1 | 12(8.2) | 0 | 12(11.5) | |
| T2 | 24(16.4) | 0 | 24(23.1) | |
| T3 | 47(32.2) | 0 | 47(45.2) | |
| T4 | 13(8.9) | 0 | 13(12.5) | |
| yp N stage | – | |||
| N0 | 87(59.6) | 42(100) | 45(43.3) | |
| N1 | 36(24.7) | 0 | 36(24.7) | |
| N2 | 14(9.6) | 0 | 14(13.5) | |
| N3 | 9(6.2) | 0 | 9(8.7) | |
| yp TNM stage | – | |||
| I | 61(41.8) | 42(100) | 19(18.3) | |
| II | 20(13.7) | 0 | 20(19.2) | |
| III | 48(32.9) | 0 | 48(46.2) | |
| IV | 17(11.6) | 0 | 17(16.3) | |
| Number of LN examined | 0.895 | |||
| Median | 25(3–75) | 24(6–48) | 25(3–75) | |
| Lymph vessel invasion | <0.001 | |||
| Yes | 28(19.2) | 1(2.4) | 27(26.0) | |
| No | 118(80.8) | 41(97.6) | 77(74.0) | |
| Perineural invasion | 0.001 | |||
| Yes | 20(13.7) | 0 | 20(19.2) | |
| No | 126(86.3) | 42(100) | 84(80.8) | |
| Adjvant chemotherapy | 0.003 | |||
| Yes | 64(43.8) | 10(23.8) | 54(51.9) | |
| No | 82(56.2) | 32(76.2) | 50(48.1) |
KPS, Karnofsky performance status; 2DRT, two-dimensional conformal radiation therapy; 3DRT, three-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; LN, lymph node.